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Abstract
A 40 year-old female, with a history of cardiac surgery for congenital aortic valve stenosis and von Willebrand’s dis-
ease (VWD) presented with increasing shortness of breath due to mixed aortic valve dysfunction. With a paucity of
such cases in the literature, we describe the successful outcome of a patient with VWD who underwent elective
redo-redo aortic root replacement with a mechanical valved conduit. She was given a three-month trial of warfarin
pre-operatively to evaluate the extent of bleeding risk. Her post-operative course was uneventful and she was dis-
charged home after six days.
Background
VWD is an autosomal dominant bleeding diathesis with
an incidence of 2-3% in the general population. The dis-
ease is characterised by a partial quantitative decrease of
qualitatively normal von Willebrand factor (VWF) and
Factor VIII (FVIII) [1]. Recently researchers have
reported that the increased shear stress resultant from a
stenotic valve causes mechanical disruption and cleavage
of VWF by ADAMTS-13, a metalloprotease enzyme
that cleaves VWF, during passage through a stenotic
orifice affecting the molecular conformation of large
VWF multimers [2,3]. There is a small and evolving lit-
erature regarding the management of patients with
VWD undergoing cardiac surgery. Our patient received
a trial of warfarin preoperatively which is a challenging
decision in the context of VWD disease. We performed
Redo-redo aortic valve replacement with a mechanical
valved conduit. The surgical procedure accompanied by
haematologist and anaesthetist input is discussed as
well.
Case presentation
A 40 year-old female with type-I VWD and factor XII
deficiency - a combination of haemostatic defects
known as ‘San Diego variant’- presented with exertional
shortness of breath, tiredness and dizzy spells. Her basal
FVIII/VWF: ristocetin cofactor and VWF Ag levels were
0.46 IU/ml and 0.40 IU/ml respectively.
At the age of 25 years, she had undergone a homo-
graft aortic valve replacement (AVR) for congenital
bicuspid aortic valve disease and severe aortic stenosis.
Soon after surgery the implanted homograft became
infected with Streptococcus Viridans causing vegetations
and a paravalvular leak resulted in a re-do homograft
AVR four months later. After the second operation she
developed complete heart block and a permanent pace-
maker was implanted. During these first two cardiac
operations she received Haemate P concentrate (CSL
Behring,UK Ltd) which is a plasma-derived FVIII con-
centrate rich in VWF, with a ratio of FVIII:C to VWF
ristocetin cofactor of 1:2.2 and no major bleeding
occurred. Since that time the patient had not suffered
from major bleeding.
Regular follow-up in 2008 revealed that the implanted
aortic homograft was degenerating. A trans-thoracic echo-
cardiogram demonstrated mixed aortic valve disease with
severe transvalvular regurgitation and a peak gradient of
59 mmHg accompanied by LV dilatation at 6.4 cm. LV
systolic function was preserved with no hypertrophy and a
mobile linear structure in the outflow tract suggesting pro-
lapse of the cusp. A contrast computed tomography (CT)
of the chest confirmed dilatation of the ascending aorta to
5 cm and it was appropriate to consider ascending aorta
root replacement with a mechanical valved conduit. To
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nists might pose bleeding problems post-operatively, she
was warfarinised pre-operatively for a period of three
months with an International Normalised Ratio (INR)
range 2.0-3.0. After the trial period of warfarin had
demonstrated no significant bleeding episodes, cardiac
surgery was planned.
Following administration of 1000 IU FVIII/VWF con-
centrate prior to induction she was taken to the operat-
ing room where, under general anaesthesia, re-opening
of sternotomy was performed. She was placed on cardio-
pulmonary bypass (CPB) via femoro-atrial cannula with
full heparinisation at 300 IU/Kg and cooled to 32°C.
The heart was densely adherent and required careful
dissection. Aortic cross-clamp was applied distally
beyond the dilated ascending aorta root and 500 ml of
cold blood cardioplegia administered retrogradely into
the coronary sinus to stun the heart. An aortotomy was
performed and 1000 ml cardioplegia was delivered into
the left and right coronary ostia. Most of the ascending
aorta was dissected and removed including the sub-cor-
onary inclusion homograft, which was heavily calcified.
A size 25 mm Carbo-Seal Composite (Sultzer Carbome-
dics Inc, Austin TX) was implanted and coronary
arteries on Carell patches re-attached to the neo-aorta.
Cross clamp and bypass time were recorded at 132 and
156 minutes respectively. Post-bypass another 1000 IU
of FVIII/VWF concentrate was given to ensure adequate
replacement of VWF. Heparin was reversed in the usual
manner with protamine 300 mg. The patient came off
bypass uneventfully; however the suture lines continued
to bleed due to a coagulopathic state confirmed by
thromboelastography (TEG) requiring Fresh Frozen
Plasma (FFP) and Bio-Glue (Cryolife Inc, Kennesaw
GA). She was transferred to the Intensive Treatment
Unit haemodynamically stable. Coagulation parameters
are given in table 1.
Two chest drains were removed safely on day one
when the total blood loss was 2250 ml. In total, four
units of packed red blood cells; three units of FFP and
two units of platelets were given, in view of coagulopa-
thy and anaemia. VWF levels were maintained above
100% throughout the operation and remained above
100% for over 5 days post-operatively without the need
for exogenous factor administration beyond those
already stated peri-operatively. Thromboprophylaxis
using unfractionated heparin (25000 IU/2 ml) 5000 IU
three times a day subcutaneously was commenced on
post-operative day (POD) one and then she was warfari-
nised the same day aiming for an INR range of 2.0-3.0.
Her post-operative course was uneventful and she was
discharged home on POD 6 when her INR was within
the therapeutic range. The patient was very well and
asymptomatic six weeks later at a follow up visit with
no bleeding or thrombotic events reported.
Conclusion
Due to a previous satisfactory response to FVIII/VWF
concentrate and contraindication of desmopressin in
patients with cardiac insufficiency because of fluid reten-
tion [4], FVIII/VWF concentrate was chosen as the
treatment of choice to prevent peri- and post-operative
bleeding. The replacement therapy can be monitored by
factor assays performed in a specialist haemostasis
laboratory [5]. Such assays require a turnaround time of
approximately one hour and are essential to enable opti-
mal control of factor levels and dosing.
Clinically bleeding severity correlates with a reduction
of VWF ristocetin cofactor and FVIII:C. Generally it is
preferable to avoid anticoagulation in patients with
VWD due to increased risk of bleeding. However in
view of the patient’s young age and previous homograft
root replacement it was felt unwise to consider further,
potentially multiple, redo homograft root replacements,
and a mechanical valve was the prosthesis of choice.
Our pre-operative evaluation of the patient required a
3-month period of observation whilst on warfarin to
ensure that anti-coagulation could be controlled without
major problems.
Our case demonstrates that complex cardiac surgery
can be performed in patients with underlying congenital
coagulopathy, and that a successful outcome requires
close multidisciplinary cooperation in terms of planning
and monitoring peri-operative factor replacement ther-
apy, the dilemma regarding the type of prosthetic valve
Table 1 Pre- and post-operative hematological
parameters
Coagulation profile Pre-
op
Post
CPB
Discharge
Hb
115-165 g/L
117 77 106
Activated partial thromboplastin time
(APTT)
26-36 secs
39 25 37
INR 1.2 1.2 2.6
FVIII: C
0.5 - 1.5 IU/ml
0.59 0.67 1.43
Factor IX: C
0.7-1.4 IU/ml
0.71 - -
Factor XII assay
25 - 250 U/dl
16.4 - -
FVIII/VWF: ristocetin cofactor assay
0.42 - 1.22 IU/ml
0.46 0.32 1.84
Pre-operative ristocetin induced platelet aggregation was normal with 79%
aggregation at a ristocetin concentration of 1.5 mg/ml; VWF collagen binding
was 43%
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operatively.
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